No Data
No Data
Longboard Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Express News | Longboard Pharmaceuticals Inc : Evercore ISI Raises Target Price to $57 From $44
Express News | Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $57 From $44, Maintains Outperform Rating
Longboard Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Express News | B. Riley Securities Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $36